If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Nasonex Spray Approved for Nasal Allergy Symptoms in U.K., France MADISON, N.J., April 14 -- Schering-Plough Corporation has received marketing authorization from the United Kingdom's Medicines Control Agency and the French Medicine Agency for Nasonex(TM) (mometasone furoate monohydrate) Aqueous Nasal Spray. Nasonex is a new once-daily nasal corticosteroid for the treatment of seasonal allergic and perennial rhinitis. In the U.K., the product is also authorized for the prevention of seasonal allergic rhinitis. Nasonex, an anti-inflammatory nasal steroid, provides relief of nasal discharge, congestion, itching and sneezing associated with rhinitis (hay fever). Unlike many currently available nasal steroids, which may take several days to provide symptom relief, Nasonex has a rapid onset of action that enables many patients to achieve clinically significant relief within 12 hours of the initial dose. The U.K. and French health authorities have determined that the safety and efficacy of Nasonex were demonstrated based on more than 20 clinical studies involving more than 3,000 patients worldwide, 12 years of age and older, including specific populations such as the elderly. Because of its negligible absorption into the bloodstream -- lower than for any other nasal steroid -- Nasonex has a highly favorable side-effect profile. After prolonged daily use for up to 52 weeks, Nasonex produced no significant systemic adverse effects. Local side effects, including nasal irritation and burning often associatedwith other steroids, were similar to placebo. The active ingredient in Nasonex -- mometasone furoate monohydrate – was discovered and developed by Schering-Plough Research Institute. In the United States, a marketing application for Nasonex nasal spray for the treatment of seasonal and perennial rhinitis was filed with the Food and Drug Administration in October 1996, and clinical trials are under way in pediatric patients. Clinical studies are also being conducted with an oral inhaled formulation of mometasone furoate for the treatment of asthma. Schering-Plough Pharmaceuticals is the pharmaceutical research and marketing unit of Schering-Plough Corporation. Schering-Plough Corporation is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.
|
